UMN Pharma Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 49

UMN Pharma Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “UMN Pharma Inc. - Product Pipeline Review - H2 2011” provides data on the UMN Pharma Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, UMN Pharma Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from UMN Pharma Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- UMN Pharma Inc. - Brief UMN Pharma Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of UMN Pharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of UMN Pharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the UMN Pharma Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate UMN Pharma Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of UMN Pharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the UMN Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with UMN Pharma Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of UMN Pharma Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of UMN Pharma Inc.; UMN Pharma Inc. - Key Therapeutics; UMN Pharma Inc. - Pipeline Overview and Promising Molecules; UMN Pharma Inc. - News; UMN Pharma Inc. - Latest Updates; UMN Pharma Inc. - Pipeline; UMN Pharma Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
UMN Pharma Inc. Snapshot
UMN Pharma Inc. Overview
Key Information
Key Facts
UMN Pharma Inc. – Research and Development Overview
Key Therapeutic Areas
UMN Pharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
UMN Pharma Inc. – Pipeline Products Glance
UMN Pharma Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
UMN Pharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
UMN Pharma Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
UMN Pharma Inc. – Drug Profiles
FluBlok
Product Description
Mechanism of Action
PanBlok
Product Description
Mechanism of Action
UMN-02
Product Description
Mechanism of Action
R&D Progress
UMN-03
Product Description
Mechanism of Action
R&D Progress
UMN-0501
Product Description
Mechanism of Action
R&D Progress
UMN-0502
Product Description
Mechanism of Action
R&D Progress
UMN-0503
Product Description
Mechanism of Action
R&D Progress
UMN Pharma Inc. – Pipeline Analysis
UMN Pharma Inc. – Pipeline Products by Therapeutic Class
UMN Pharma Inc. - Pipeline Products By Target
UMN Pharma Inc. – Pipeline Products by Route of Administration
UMN Pharma Inc. – Pipeline Products by Molecule Type
UMN Pharma Inc. – Recent Pipeline Updates
UMN Pharma Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 20, 2010: UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial
Jun 18, 2008: UMN Pharma Initiates Phase I/II Trials for Pandemic Influenza Vaccine Manufactured from Cell-culture, UMN-0501
Feb 13, 2009: UMN Pharma Presents Favorable Results From Phase I/II Study Of UMN-0501
Mar 09, 2006: Crucell And DSM Biologics Announce Per C6 Licensing Agreement With UMN Pharma
Oct 05, 2009: UMN Pharma Initiates Phase II Clinical Trial For Avian Influenza A (H5N1) Vaccine Manufactured From Cell-Culture, UMN-0501
Financial Deals Landscape
UMN Pharma Inc., Deals Summary
UMN Pharma Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
UMN Pharma Secures $19 Million In Series C Financing
UMN Pharma Secures $7.5 Million In Series B-2 Financing Round
UMN Pharma Secures $1 Million In Series B-1 Financing Round
UMN Pharma Raises $1.8 Million In Series A Financing
Partnerships
Astellas Pharma Enters Into Co-Development Agreement With UMN Pharma
UMN Pharma Enters Into Co-Development Agreement With API
UMN Pharma Forms Joint Venture With IHI
Licensing Agreements
Crucell And DSM Biologics Enter Into Licensing Agreement With UMN Pharma
Protein Sciences Expands Its Licensing Agreement With UMN Pharma For FluBlok And PanBlok
Protein Sciences Enters Into Licensing Agreement With UMN Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
UMN Pharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
UMN Pharma Inc. – Pipeline by Stage of Development, H2 2011
UMN Pharma Inc. – Monotherapy Products in Pipeline, H2 2011
UMN Pharma Inc. – Filed, H2 2011
UMN Pharma Inc. - Phase II, H2 2011
UMN Pharma Inc. - Pipeline By Therapeutic Class, H2 2011
UMN Pharma Inc. - Pipeline By Target, H2 2011
UMN Pharma Inc. – Pipeline By Route of Administration, H2 2011
UMN Pharma Inc. – Pipeline By Molecule Type, H2 2011
UMN Pharma Inc. – Recent Pipeline Updates, H2 2011
UMN Pharma Inc., Other Locations
UMN Pharma Inc., Subsidiaries
UMN Pharma Inc., Deals Summary
UMN Pharma Secures $19 Million In Series C Financing
UMN Pharma Secures $7.5 Million In Series B-2 Financing Round
UMN Pharma Secures $1 Million In Series B-1 Financing Round
UMN Pharma Raises $1.8 Million In Series A Financing
Astellas Pharma Enters Into Co-Development Agreement With UMN Pharma
UMN Pharma Enters Into Co-Development Agreement With API
UMN Pharma Forms Joint Venture With IHI
Crucell And DSM Biologics Enter Into Licensing Agreement With UMN Pharma
Protein Sciences Expands Its Licensing Agreement With UMN Pharma For FluBlok And PanBlok
Protein Sciences Enters Into Licensing Agreement With UMN Pharma

List of Figures
UMN Pharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
UMN Pharma Inc. – Pipeline by Stage of Development, H2 2011
UMN Pharma Inc. – Monotherapy Products in Pipeline, H2 2011
UMN Pharma Inc. – Pipeline By Therapeutic Class, H2 2011
UMN Pharma Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Analysis of Google Inc
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Dell Inc.